论文部分内容阅读
德国 Christian-Albrechts 大学的 Stefan Schreiber 教授及其同事在一项Ⅱ期研究中对291例中度至重度节段性回肠炎患者皮下给予抗肿瘤坏死因子(TNF)单克隆抗体 Certolizumab pegol(CDP870)的安全性和有效性进行了评估;结
In a Phase II study, 291 patients with moderate-to-severe Crohn’s disease were subcutaneously given the anti-tumor necrosis factor (TNF) monoclonal antibody Certolizumab pegol (CDP870) by Professor Stefan Schreiber of the Christian-Albrechts University in Germany and colleagues Safety and effectiveness were evaluated;